![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Monday, July 24, 2023 12:50:59 PM
From the paper: "In accordance with the National Comprehensive Cancer Network, the current optimal treatment for patients with metastatic HER2 exon 20 insertion mutation, in second line, T-DXd, seems to be most appropriate. Nevertheless, HER2-specific TKIs with better selectivity and reduced toxicity are expected to yield at least similar outcomes in the near future. In the interim, poziotinib presents a treatment option that should not be disregarded entirely. It is crucial to explore the patient population and dosages for which this strategy can offer a beneficial effect while maintaining an acceptable quality of life."
https://www.jto.org/article/S1556-0864(23)00548-8/fulltext
Should ASRT work on Pozi?
Recent SPPI News
- Form 15-12G - Securities registration termination [Section 12(g)] • Edgar (US Regulatory) • 11/09/2023 10:00:17 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 09/28/2023 04:15:27 AM
- Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments • Edgar (US Regulatory) • 09/26/2023 09:23:08 PM
Glidelogic Corp. Announces Revolutionary AI-Generated Content Copyright Protection Solution • GDLG • Jul 26, 2024 12:30 PM
Southern Silver Files NI43-101 Technical Report for its Updated Preliminary Economic Assessment for the Cerro Las Minitas Project • SSV • Jul 25, 2024 8:00 AM
Greenlite Ventures Completes Agreement with No Limit Technology • GRNL • Jul 19, 2024 10:00 AM
VAYK Expects Revenue from First Airbnb Property Starting from August • VAYK • Jul 18, 2024 9:00 AM
North Bay Resources Acquires Mt. Vernon Gold Mine, Sierra County, California, with Assays up to 4.8 oz. Au per Ton • NBRI • Jul 18, 2024 9:00 AM
Nightfood Holdings Signs Letter of Intent for All-Stock Acquisition of CarryOutSupplies.com • NGTF • Jul 17, 2024 1:00 PM